Portal de Periódicos da CAPES

THE EVOLVING ROLE OF ALPHA INTERFERON IN THE TREATMENT OF MALIGNANCIES

1986; Wiley; Volume: 16; Issue: 3 Linguagem: Inglês

10.1111/j.1445-5994.1986.tb01212.x

0004-8291

Peter Hersey,

Immunotherapy and Immune Responses

Australian and New Zealand Journal of MedicineVolume 16, Issue 3 p. 425-437 THE EVOLVING ROLE OF ALPHA INTERFERON IN THE TREATMENT OF MALIGNANCIES P. HERSEY, Corresponding Author P. HERSEY Oncology and lmmunology Unit, Royal Newcastle Hospital*Dr Peter Hersey, Oncology and Immunology Unit, David Maddison Clinical Sciences Building, Royal Newcastle Hospital, Newcastle, NSW 2300.Search for more papers by this author P. HERSEY, Corresponding Author P. HERSEY Oncology and lmmunology Unit, Royal Newcastle Hospital*Dr Peter Hersey, Oncology and Immunology Unit, David Maddison Clinical Sciences Building, Royal Newcastle Hospital, Newcastle, NSW 2300.Search for more papers by this author First published: June 1986 https://doi.org/10.1111/j.1445-5994.1986.tb01212.xCitations: 15AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 Strander H., Cantell K., Lngimarson S. Interferon treatment of osteogenic sarcoma: a clinical trial. Conference on modulation of host immune resistance in the prevention and treatment of induced neoplasias.Washington DC: U.S. Government printing office 1974; 28: 377–81. 2 Strander H. Interferons: antineoplastic drugs. Blut 1977; 35: 288–99. 3 Merigan TC, Sikora K., Breeden JH, Levy R., Rosenburg SA. Preliminary observations on the effect of human leukocyte interferon in non Hodgkin's lymphoma. N Engl J Med 1978; 299: 1449–53. 4 Mellstedt H., Bjorkholm M., Johansson B., Ahre A., Holm G., Strander H. Interferon therapy in myelomatosis. Lancet 1979; 1: 245–7. 5 Gutterman J., Blumenschein GR, Alexanian R., et al. Leukocyte interferon-induced tumour regression in human metastatic breast cancer, multiple myeloma and malignant lymphoma. Ann Intern Med 1980; 93: 399–406. 6 Sikora K. Does interferon cure cancer Br Med J 1980; 281: 855–8. 7 Cantell K., Hirvonen S. Large scale production of human leukocyte interferon containing 10 units/ml. J Gen Virol 1978; 39: 541–3. 8 Lawn RM, Adelman J., Dull TJ, Cross M., Goeddel D., Ullrich A. A DNA sequence of 2 closely linked human leukocyte interferon genes. Science 1981; 212: 1159–65. 9 Toy JL. The interferons. Clin Exp lmmunol 1983; 54: 1–13. 10 Sherwin SA, Foon KA, Abrams PG, et al. A preliminary phase I trial of partially purified interferon in patients with cancer. J Biol Resp Modifiers 1984; 3: 599–607. 11 Gutterman JU, Rosenblum MG, Rios A., Fritsche HA, Quesada JR. Pharmacokinetic study of partially pure interferon in cancer patients. Cancer Res 1984; 44: 4164–71. 12 Borden EC, Hawkins MJ, Homing S., et al. Phase I trial of serine substituted recombinant interferon beta. Proc Annu Meet Am Soc Clin Oncol 1984; 3: 58. 13 Revel M., Bash D., Ruddle FH. Antibodies to a cell surface component coded by chromosome 21 inhibit action of interferon. Nature 1985; 260: 139–41. 14 Revel M., Kimchi A., Shulman L. Role of interferon induced enzymes in the antiviral and antimitogenic effects of interferon. Ann NY Acad Sci 1980; 350: 349–72. 15 Pegg AE, McCann PP. Polyamine metabolism and function. Am J Physiol 1982; 243: 212–21. 16 Zoon KC, Arnheiter H. Studies of the interferon receptors. Pharmacol Ther 1984; 24: 259–78. 17 Tovey MG, Dron M., Mogensen KE, Lebleu B., Mechti N., Begon Lours-Guymarho J. Isolation of Dandi cells with reduced sensitivity to interferon 11. On the mechanisms of resistance. J Gen Virol 1983; 64: 2649–53. 18 Foon KA, Sherwin SA, Abrams PG, et al. Treatment of advanced non-Hodgkins lymphoma with recombinant leukocyte A interferon. N Engl J Med 1984; 311: 1148–52. 19 Bunn PA, Foon KA, Inde DC, et al. Recombinant leukocyte A interferon. An active agent in advanced cutaneous T-cell lymphomas. Ann Intern Med 1984; 101: 484–7. 20 Salmon SE, Durie BGM, Young L., Liu RM, Trown PW, Stebbing N. Effects of cloned human leukocyte interferons in the human tumor stem cell assay. J Clin Oncol 1983; 1: 217–25. 21 Willson JKV, Bittner G., Borden EC. Antiproliferative activity of human interferons against ovarian cancer cells grown in human tumor stem cell assay. J Interferon Res 1984; 4: 441–7. 22 Tyring SK, Klimpel G., Brysk M., et al. Eradication of cultured human melanoma cells by immune interferon and leukocytes. J Natl Canc Inst 1984; 73: 1067–73. 23 Quesada JR, Hersh EM, Gutterman JU. Biologic therapy of hairy cell leukemia. Semin Oncol 1984; 11 (Suppl. 2): 507–10. 24 Hamlyn P., Sikora K. Oncogenes. Lancet 1983; 2: 326–9. 25 Jonak GJ, Knight E. Jr. Selective reduction of c-myc MRNA in Dandi cells by human beta interferon. Proc Natl Acad Sci USA 1984; 81: 1747–50. 26 Kimchi A., Resnitsky D., Bendori R., Einat M. Down regulation of the c-myc and the p53 genes by IFN is tightly associated with IFN mediated GO/GI arrest. Antiviral Res 1984; Abstr. 1, No. 3: 57. 27 Krueger LJ, Bresser J., Andryuk PJ, Gillespie DH. Interferon induced oncogene regulation: the gene bank hypothesis. J Cell Biochem 1984; Suppl 8A: 85. 28 Tominaga S., Lengyel P. Genes activated by interferon. J Biol Chem 1985; 260: 1975–8. 29 Samid D., Chang EH, Schaff Z., Friedman RM. Biochemical correlates of reversion in interferon treated mouse cells transformed by a human oncogene. Lymphokine Res 1984; 3: 1009. 30 Castaigne S., Sigaux F., Cantell K., et al. Interferon alfa-2a treatment in hairy cell leukemia. Cancer 1986; 57: (In press). 31 Ball ED, Guyre PM, Shen L., et al. Gamma interferon induces monocytoid differentiation in the HL-60 cell line. J Clin Invest 1984; 73: 1072–7. 32 Takano S., Nagano Y. Differentiation in mouse leukemia cells mediated by an immune interferon preparation. J Interferon Res 1984; 4: 383–8. 33 Metcalf D., Nicola NA. Autoinduction of differentiation in WEH1–3B leukaemia cells. Int J Cancer 1982; 30: 773–80. 34 Talpaz M., McCredie K., Kantarjian H., Trujillo J., Keating M., Gutterman J. Chronic myelogenous leukaemia: haematologic remissions with alpha interferon. Br J Haematol (In press). 35 Ortaldo JR, Mantovani A., Hobbs D., Rubinstein M., Pestka S., Herberman RB. Effects of several species of human leukocyte interferon on cytotoxic activity of NK cells and monocytes. Int J Cancer 1983; 31: 285–9. 36 Herbermann RB, Djeu JY, Ortaldo JR, Holden HT, West WH, Bonnard GD. Role of interferon in augmentation of natural and antibody-dependent cell-mediated cytotoxicity. Cancer Treat Rep 1978; 62: 1893–6. 37 Warren R., Kalamasz D., Storb R. Enhancement of human ADCC with interferon. Clin Exp Immunol 1982; 50: 183–8. 38 Coleman DL, Ernstoff MS, Kirkwood JM, Ryan JL. Effect of intravenous recombinant alpha 2 interferon on monocyte Fc-dependent phagocytosis in patients with malignant melanoma. J Interferon Res 1984; 4: 215–21. 39 Rhodes J., Jones DH, Bleehan NM. Increased expression of human monocyte HLA-DR antigens and Fc gamma receptors in response to human interferon in vivo. Clin Exp Immunol 1983; 53: 739–43. 40 Hersey P., Murray E., Grace J., McCarthy WH. Current research on immunopathology of melanoma: analysis of lymphocyte populations in relation to antigen expression and histological features of melanoma. Pathology 1985; 17: 385–91. 41 Vose BM, Moore M. Human tumor-infiltrating lymphocytes: a marker of host response. Semin Hematol 1985; 22: 27–40. 42 Brunda MJ, Rosenbaum D., Stern L. Inhibition of experimentally-induced murine metastases by recombinant alpha interferon: correlation between the modulatory effect of interferon treatment on natural killer cell activity and inhibition of metastases. Int J Cancer 1984; 34: 421–6. 43 Hersey P., Edwards A., Milton GW, McCarthy WH. No evidence for an association between natural killer cell activity and prognosis in melanoma patients. Natural Immunity Cell Growth Regulation 198384; 3: 87–94. 44 Hersey P., Hasic E., MacDonald M., et al. Effects of recombinant leukocyte interferon (rIFN-alpha) on tumor growth and immune responses in patients with metastatic melanoma. Br J Cancer 1985; 51: 815–26. 45 Hokland P., Hokland M., Olesen BK, Ernst P. Effect of recombinant alpha interferon on NK and ADCC function in lung cancer patients: Results from a phase II trial. J Interferon Res 1984; 4: 561–9. 46 Maluish AE, Ortaldo JR, Conlon JC. Depression of natural killer cytotoxicity after in vivo administration of recombinant leukocyte interferon. J Immunol 1983; 131: 503–7. 47 Bolhuis RLH, Van De Griend RJ, Gravekamp C. Modulation of cytolytic activity of T3– natural killer cell derived clones by interferon. 14th International Chemotherapy Congress. 1985; Abstr. No. WS-2-6. 48 Vanky F., Argov S. Human tumor-lymphocyte interaction in vitro VII. Blastogenesis and generation of cytotoxicity against autologous tumor biopsy cells are inhibited by interferon. Int J Cancer 1980; 26: 405–11. 49 Brenan M., Zinkernagel RM. Influence of one virus infection on a second concurrent primary in vivo antiviral cytotoxic T-cell response. Infect lmmun 1983; 41: 470–5. 50 Thomas HC, Ikeda T., Caruso L. Response to interferon alpha-2A in interferon-deficient chromic HBV carriers. Symposium “Developments in the treatment of malignant and viral disorders with recombinant interferon”. Osaka, Jpn, June 22, 1985. 51 Giacomini P., Aguzzi A., Pestka S., Fisher PB, Ferrone S. Modulation by recombinant DNA leukocyte (α) and fibroblast (β) interferons of the expression and shedding of HLA and tumor-associated antigens by human melanoma cells. J Immunol 1984; 133: 1649–55. 52 Herlyn M., Guerry D., Koprowski H. Recombinant interferon induced changes in expression and shedding of antigens associated with normal human melanocytes, nevus cells and metastatic melanoma cells. J Immunol 1985; 134: 4226–9. 53 Greiner JW, Hand PH, Noguchi P., Fisher PB, Pestka S., Schlom J. Enhanced expression of surface tumor-associated antigens on human breast and colon tumor cells after recombinant human leukocyte alpha interferon treatment. Canc Res 1984; 44: 3208–14. 54 Blomgren H., Einhorn S. Lymphokine production by PHA-stimulated human lymphocytes is enhanced by interferon. Int Arch Allergy Appl Immunol 1981; 66: 173–8. 55 Grim EA, Mazumder A., Zhang HZ, Rosenberg SA. Lymphokine-activated killer cell phenomenon. Lysis of natural killer resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med 1982; 155: 1823–41. 56 Hersey P., Bindon C., Edwards A., Murray E., Phillips G., McCarthy W. Induction of cytotoxic activity in human lymphocytes against autologous and allogeneic melanoma cells in vitro by culture with interleukin 2. Int J Cancer 1981; 28: 695–703. 57 Neefe JR, Sullivan JE, Ayoob M., Phillips E., Smith FP. Augmented immunity in cancer patients treated with alpha-interferon. Cancer Res 1985; 45: 874–8. 58 Hersey P., MacDonald M., Hall C., et al. Immunological effects of recombinant interferon alpha 2a (rIFN-α2a) in patients with disseminated melanoma. Cancer (In press). 59 Quesada JR, Reuben J., Manning JT, Hersh EM, Gutterman JU. Alpha interferon for induction of remission in hairy-cell leukemia. N Engl J Med 1984; 310: 15–8. 60 Catovsky D. Prolymphocytic and hairy cell leukemias. In: FW Gunz, ES Henderson, Eds. Leukemia. New York : Grune and Stratton, 1983; 759–81. 61 Gutterman JU. Therapy of hairy cell leukemia with interferon alpha-A. Proceedings of symposium “Developments in the treatment of malignant and viral disorders with recornbinant interferon”. Osaka, Jpn, June 22, 1985. 62 Ratain MJ, Golomb HM, Vardiman JW, Vokes EE, Jacobs RH, Daly K. Treatment of hairy cell leukemia with recombinant alpha 2 interferon. Blood 1985; 65: 644–8. 63 Jacobs AD, Hamplin RE, Golde DW. Recombinant alpha 2 interferon for hairy cell leukemia. Blood 1985; 65: 1017–20. 64 Mellstedt H., Ahre A., Bjorkholm M., et al. Interferon therapy in patients with myeloma. In: WD Terry, SA Rosenburg, Eds. lmmunology of human cancer. New York : Elsevier North Holland Inc. 1982; 387–91. 65 Ahre A., Bjorkholm M., Mellstedt H., et al. Human leukocyte interferon and intermittent high-dose melphalan-prednisone administration in the treatment of multiple myeloma: a randomized clinical trial from the myeloma group of central Sweden. Cancer Treat Rep 1984; 68: 1331–8. 66 Constanzi JJ, Cooper M., Ozer H., Spiegel RJ, Pollard RB. The use of recombinant alpha-2 interferon in patients with resistant and relapsing multiple myeloma. J Clin Oncol 1985; 3: 654–9. 67 Quesada JR, Alexanian R., Hawkins M., Barlogie B., Borden E., Gutterman J. Treatment of multiple myeloma with recombinant alpha interferon. Blood 1986(In press). 68 Ohno R., Kimura K. Treatment of multiple myeloma with interferon alpha-2a. Cancer Treat Rep 1986(In press). 69 Louie AC, Gallagher JG, Sikora K., Levy R., Rosenberg SA, Merrigan TC. Follow up observations on the effect of human leukocyte interferon in non-Hodgkin's lymphoma. Blood 1981; 58: 712–8. 70 Quesada JR, Hawkins M., Homing S., et al. Collaborative phase I-II study of recombinant DNA-produced leukocyte interferon (clone A) in metastatic breast cancer, malignant lymphoma and multiple myeloma. Am J Med 1984; 77: 427–33. 71 Ozer H., Ratanatharajhorn V., Leavitt R. A phase II trial of rDNA alpha 2 interferon in low grade non-Hodgkin's lymphoma. Proc Am Soc Clin Oncol 1983; 2: 215. 72 Merigan RC, Homing S. Clinical experience with interferons in human malignancy at Stanford. Antiviral Res 1984; Special Abstr. Issue: 32. 73 Lutzner M., Edelson R., Schein P., Green I., Kirkpatrick C., Ahmed A. Cutaneous T cell lymphomas. The Sézary syndrome, mycosis fungoides and related disorders. Ann Intern Med 1975; 83: 534–52. 74 Bunn PA, Huberman MS, Whang Peng J. Prospective staging evaluation of patients with cutaneous T-cell lymphomas: demonstration of a high frequency of extracutaneous dissemination. Ann Intern Med 1980; 93: 223–30. 75 Haynes BF, Metzgar RS, Minna JD, Bunn PA. Phenotypic characterization of cutaneous T-cell lymphomas. Use of monoclonal antibodies to compare with other malignant T-cells. N Engl J Med 1981; 304: 1319–23. 76 Farnarier-seidel C., Kaplanski S., Goldstein M., Jancovici E., Sayag T., Deprieds R. An OKT4+ T-cell population with suppressor activity in Sezary syndrome. Scand J Immunol 1983; 18: 389–98. 77 Talpaz M., McCredie KB, Mavligit GM, Gutterman JU. Leukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukaemia. Blood 1983; 62: 689–96. 78 Talpaz M., Kantargian H., McCredie KB, Keating MJ, Trujillo J., Gutterman JU. Clinical study of human alpha interferon in chronic myelogenous leukemia. Am Soc Hemat 27th Annual Meeting (abstract submitted). 79 Friedman-Kien AE, Laubenstein LJ, Rubinstein P., et al. Disseminated Kaposi's sarcoma in homosexual men. Ann Intern Med 1982; 96: 693–700. 80 Krown SE, Real FX, Cunningham-Rundles S., et al. Preliminary observations on the effect of recombinant leukocyte A interferon in homosexual men with Kaposi's sarcoma. N Engl J Med 1983; 308: 1071–6. 81 Real FX, Krown SE, Krim M., Myskowski PL, Safai B., Oettgen HG. Treatment of Kaposi's sarcoma with recombinant leukocyte A interferon (RIFN-alpha). Proc Ann Meet Am Soc Clin Oncol 1984; 3: 55. 82 Destefano E., Friedman RM, Freidman-mien AE. Acid labile human leukocyte interferon in homosexual men with Kaposi's sarcoma and lymphadenopathy. J Infect Dis 1981; 146: 451–9. 83 Groopman JE, Gottlieh, MS, Goodman J. et al. Recombinant alpha-2 interferon therapy for Kaposi's sarcoma assoclated with the acquired immunodeficiency syndrome. Ann Intern hled 1984: 100: 671–6. 84 Volberding P. Alpha interferon therapy ot Kapoli's barcoma in AIDS. J Cell Riocheni 1984; Suppl 8A: 9. 85 Kidhart JA. Interferons In the treatment of renal cell carcinoma. In Symposium “Developments in the treatment of malignant and viral disorders with recombinant interferon”. Osaka, Jpn. June 22, 1985. 86 Quesada JK, Swanson DA, Trindale A., Guttcrman JV. Renal carcinoma: anti tumour effects of leukocyte inrerferon. Canccr Res 1983; 43: 940–3. 87 Quesada JK, Swanson DA, Gutterman JU. Phaie II study of interferon alpha in metastatic renal cell carcinoma. A progres, report. J Clin Oncol 1985; 3: 1086–92. 88 Kirkwood JM, Harris J., Vera A., et al. Kandomized trial of two doses of leukocyte interferon in metastatic renal cell carcinoma. The American Cancer Societ) collahorative trial. Cancer Res 1985; 45: 863–71. 89 Quesada JR, Rioh A., Swanson D., Trown P. Gutterman JU. Antitumour activity of recombinant-derived interferon alpha (rlFN-αA) in metastatic renal carcinoma. J Clin Oncol 1985; 3: 1522–8. 90 Krown SE, Einzig Al, Abramson JD. Treatment of advanced renal cell cancer wiih recombinant alpha interferon. Proc Am Assoc Cancer Kes 1983; 24: 195. 91 Neidhart JA, Gagen MM, Young D. et al. Interferon alpha therapy of renal carcinoma. Cancer Res 1984; 44, 4140–3. 92 Fossa S., De Garis S., Lleter MS. et al. Recombinant interferon alfa-2a Hith or without vinhlasiine in metastatic renal cell carcinoma. Cancer 1986(In press). 93 Krown S., Burkc M., Kirkwood JM. et al. Human leukocyte (alpha) interferon in metastatic malignant melanoma. The American Cancer Society Phase II Trial. Cancer Treat Rep 1984; 68: 723–6. 94 Retsas S. Priesrman TJ, Newton KA, Westbury G. Evaluation of human lymphohlactoid interferon in advanced malignant melanoma. Cancer 1983; 51: 273–6. 95 Creagan ET, Ahmann DL, Green SJ, et al. Phase II study of recombinant leukocyte A interferon (rlFN-αA) in disseminated malignant melanoma. Cancer 1984; 54: 2844–9. 96 Creagan ET, Ahmann DL, Green SJ, et al. Phase II study of “low dose” recombinant leukocyte A interferon (rlFN-αA) in disseminated malignant melanoma. Am J Clin Oncol 1984b; 2: 1002–5. 97 Coates A., Rallings M., Hersey P., Swanson C. Phase II study of recombinani alpha-2 interferon in advanced malignant melanoma. J Interferon Kes 1985(In press). 98 Hawkins MJ, McCune CS. Speyer JL, Sorell M. Recombinant alpha-2 interferon (IFN-alpha 2) (SCH 30500) in parienrs with metastatic malignant melanoma (MMM).An ECOG pilot srudy. Pro: Ann Neet Am Soc Clin Oncol 1984; 3: 51. 99 Robinson WA, Kirkwood J., Harvey H., et al. Effective use of recoinhinant human alpha 2 interferon (IFN alpha 2) in metastatic malignant melanoma (MMM). A comparison of 2 regimens. Proc Annu Meet Am Soc Clin Onsol 1984; 3: 60. 100 Pouillart P., Bretaudeau B., Dorval T., et al. Clinical phase II study of recombinant DNA inrerfcron (H.U. IFN-alpha 2) in patients with metaslatic malignant melanoma. Antiviral Res 1984; No. 3, abrtr: 19. 101 Ernstoff MS, Reisr M., David CA. Intravenous recombrnant alpha 2 interferon in metastaric melanoma. Proc Am Soc Clin Oncol 1983; 19: 222. 102 Rorden EC, Holland JF, Dao TL. Leukocyte derived interferon (alpha) in human breast carcinoma. The American Cancel Society phase II trial. Ann Intern Med 1982; 97: 1–6. 103 Sherwin SA, Knost JA. Fein S. A multiple-dose phase 1 trial of recomhinant leukocyte A interferon in caticer patients. JAMA 1982; 248: 2461–6. 104 Padmanabhan N., Ralkwill FR, Boomer JG. Rubens RD. Recombinant DNA human interferon alpha 2 in advanced breast cancer: a phase 2 trial. Br J Cancer 1985; 51: 55–60. 105 Muss H. Caponera M. Sruart J. Intravenous alpha 2 (rlFN-α2) in patients with advanced breast cancer. A phase II study. Proc Am Soc Clin Oncol 1983; 2: 99. 106 Nethersell A., Smedley H., Katrak M., Wheeler T. Sikora K. Recombinant interferon in adbanced breast cercinoma. Rr J Cancer 1984; 49: 615–20. 107 Sarna G., Figlin R., Callaghan M. Alpha (human leukocyte) interferon as treatment of non small cell carcinoma of the lung. A phase II trial. J Biol Response Mod 1983; 2: 343–7. 108 Ernst P., Olesen BK, Nissen MH, Hokland P., Justesen J., Hansen HH. In vivo effect of recombinant interferon alpha (IFN) in patients with lung cancer. Proc Annu Meet Soc Clin Oncol 1984; 3: 66. 109 Grunberg SM, Kempf RA, Venturi CL, Itri LM. Phase II trial of recombinant interferon alpha (IFN-αA) in advanced non-small cell lung cancer. Proc Annu Meet Am Soc Clin Oncol 1984; 3: 63. 110 Leavitt RD, Duffey P., Aisner J. A phase II study of recombinant leukocyte A interferon in non-small cell carcinoma of the lung. Proc Annu Meet Am Soc Clin Oncol 1984; 3: 52. 111 Mattson K., Holsti LR, Niiranen A., Pyrhonen S., Holsti P., Cantell K. Maintenance interferon (IFN) vs maintenance chemotherapy (CT) following induction chemotherapy and consolidation radiotherapy (RT) in small cell lung cancer (SCLC). Proc Annu Meet Am Soc Clin Oncol 1984; 3: 48. 112 Silgals RM, Ahlgren JD, Neefe JR, et al. A phase II trial of high dose intravenous interferon alpha-2 in advanced colorectal cancer. Cancer 1984; 54: 2257–61. 113 Lundell G., Blomgren H., Cedermark B., Silfversward C., Theve J., Ohman U. High dose rDNA human alpha 2 interferon therapy in patients with advanced colorectal adenocarcinoma: a phase II trial. Radiother Oncol 1984; 1: 325–32. 114 Niederle N., Kurschel E., Schmidt CG. Biological effects of recombined leukocyte alpha-2 interferon in metastasizing colorectal cancers. Dtsch Med Wochenschr 1984; 109: 779–82. 115 Chaplinski T., Laszlo J., Moore J., Silverman P. Phase II trial of lymphoblastoid interferon in metastatic colon carcinoma. Cancer Treat Rep 1983; 67: 1009–12. 116 Foon KA, Bottino GC, Abrams PG, et al. Phase II trial of recombinant leukocyte A interferon in patients with advanced chronic lymphocytic leukemia. Am J Med 1985; 78: 216–20. 117 Nagai M., Arai T. Clinical effects of interferon in malignant brain tumors. Neurosurg Rev 1984; 7: 55–64. 118 Bradley NJ, Darling JL, Oktar N., Bloom HJ, Thomas DG, Davies AT. The failure of human leukocyte interferon to influence the growth of human glioma cell populations in vitro and in vivo. Br J Cancer 1983; 48: 819–25. 119 Freedman RS, Gutterman JU, Wharton JT, Rutledge FN. Leukocyte interferon (IFN alpha) in patients with epithelial ovarian carcinoma. J Biol Response Mod 1983; 2: 133–8. 120 Rustin GJ, Kaye SB, Williams CJ, Newlands ES, Bagshawe KD, Toy JL. Response of differentiated but not anaplastic teratoma to interferon. Br J Cancer 1984; 50: 611–6. 121 Dinarello CA, Bernheim HA, Duff GW, et al. Mechanisms of fever induced by recombinant human interferon. J Clin Invest 1984; 74: 906–13. 122 Baracos V., Rodemann HP, Dinarello CA, Goldberg AL. Stimulation of muscle protein degradation and prostaglandin E2 release by leukocytic pyrogen (interleukin-1). N Engl J Med 1983; 308: 553–8. 123 Smith EM, Blacock JE. Human lymphocyte production of corticotropin and endorphin-like substances: association with leukocyte interferon. Proc Natl Acad Sci USA 1981; 78: 7530–4. 124 Epstein LB, Rose ME, McManus NH, Chob HL. Absence of functional and structural homology of natural and recombinant human leukocyte interferon (IFN-α) with human ACTH and β endorphin. Biochem Biophys Res Commun 1982; 104: 341–6. 125 Trown PW, Dennin RA, Kramer MJ, et al. Antibodies to human leukocyte interferons in cancer patients. Lancet 1983; 1: 81–4. 126 Forti RL, Mitchell WM, Hubbard WC, Workman RJ, Forbes JT. Pleiotropic activities of human interferons are mediated hy multiple response pathways. Proc Natl Acad Sci USA 1984; 81: 170–4. 127 Kovach JS, Svingen PA. Enhancement of the antiproliferative activity of human interferon by polyamine depletion. Cancer Treat Rep 1985; 69: 97–103. 128 Gauci L. Symposium “Developments in the treatment of malignant and viral disorders with recombinant interferon”. Osaka, Jpn, June 22, 1985. 129 Flodgren P., Borgstrom S., Johnsson PE, Lindstrom C., Strogren HO. Metastatic malignant melanoma: regression induced by combined treatment with interferon [HuIFN-α (Le)] and cimetidine. Int J Cancer 1983; 32: 657–65. 130 Hill NO, Pardue A. Interferon and cimetidine for malignant melanoma. Lancet 1983; 1: 286. 131 Slater DE, Krown SE, Pinksky CM, et al. Human leukocyte (alpha) interferon [HuIF-α(Le)] and cimetidine in malignant melanoma. Proc Am Soc Clin Oncol 1984; 3.54: C210. 132 Sunkara PS, Prakash NJ, Mayer GD, Sjoerdsma A. Tumor suppression with a combination of α-difluoromethylornithine and interferon. Science 1983; 219: 851–3. 133 Rosenblum MG, Gutterman JU. Synergistic anti-proliferative activity of leukocyte interferon in combination with α-difluoromethylornithine against human cells in culture. Cancer Res 1984; 44: 2339–40. 134 Heston WDW, Fleischmann J., Tackett RE, Ratliff TL. Effects of α-difluoromethylornithine and recombinant interferon 2 on the growth of a human renal cell adenocarcinoma xenograft in nude mice. Cancer Res 1984; 44: 3320–25. 135 Talpaz M., Quesada J., Gutterman JU. Phase I study of difluoromethylornilhine (DFMO) and leukocyte interferon (IFN alpha) in cancer patients (PTS). Proc Annu Meet Am Soc Clin Oncol 1984; 3: 63. 136 Aapro MS, Alberts DS, Salmon SE. Interactions of human leukocyte interferon with vinca alkaloids and other chemotherapeutic agents against human tumors in clonogenic assay. Cancer Chemother Pharmacol 1983; 10: 161–6. 137 Le J., Yip YK, Vilcek J. Cytolytic activity of interferon-gamma and its synergism with 5-fluorouracil. Int J Cancer 1984; 34: 495–500. 138 Namba M., Yamamoto S., Tanaka H., Kanamori T., Nobuhara M., Kimoto T. In vitro and in vivo studies on potentiation of cytotoxic effects of anticancer drugs or cobalt 60 gamma ray by interferon on human neoplastic cells. Cancer 1984; 54: 2262–7. 139 Czarniecki CW, Fennie CW, Powers DB, Estell DA. Synergistic antiviral and antiproliferative activities of Escherichia coli-derived human alpha beta and gamma interferons. J Virol 1984; 49: 490–6. 140 Aggarwal BB, Hass PE, Kohr GE, Nedwin GE, Gray D. Biochemical and biological properties of human lymphotoxin and tumor necrosis factor. 14th Int. Chemotherapy Congress, Kyoto, Jpn 1985; Abstr. SY-6–7. 141 Aggarwal BB, Kohr WJ, Hall PE, et al. Human tumor necrosis factor production, purification and characterization. J Biol Chem 1985; 260: 2345–54. 142 Ruddle NH. Lymphotoxin redux. Immunol Today 1985; 6: 156–9. 143 Lee SH, Aggarwal BB, Rinderknecht E., Assissi F., Chiu H. The synergistic antiproliferative effect of gamma interferon and human lymphotoxin. J Immunol 1984; 133: 1083–6. 144 Williams TW. In vitro synergistic effects of interferon on human lymphotoxin activity: a new property of interferon in lymphocyte mediated target cell killing. Lymphokine Res 1984; 3: 113–8. 145 Granger GA, Kobayashi M., Orr SL, Masunaka I., Plunkett M., Yamamoto RS. Human lymphotoxins: a multicomponent family of proteins with selectivity for transformed cells in vitro and in vivo. 14th International Chemotherapy Conference, Kyoto, Jpn, June 1985; Abstr. No. SY-608. 146 Houghton AN, Mintzer D., Cordon-Cardo C., et al. Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase 1 trial in patients with malignant melanoma. Proc Natl Acad Sci 1985; 82: 1242. 147 Sears HF, Mattis J., Herlyn D., et al. Phase I clinical trial of monoclonal antibody in treatment of gastrointestinal tumours. Lancet 1982; 1: 762–5. 148 Christiaansen JE, Sears DW. Unusually efficient tumor cell lysis by human effectors of antibody-dependent cellular cytotoxicity mediated by monoclonal antibodies. Cancer Res 1984; 44: 3712–8. Citing Literature Volume16, Issue3June 1986Pages 425-437 ReferencesRelatedInformation